OCULAR THERAPEUTIX INVESTOR ALERT: Legal Investigation for Potential Securities Law Violations

OCULAR THERAPEUTIX INVESTOR ALERT: Legal Investigation for Potential Securities Law Violations

Girard Gibbs LLP
Posted on: 08 Jul 17

Girard Gibbs LLP is investigating potential claims on behalf of
investors of Ocular Therapeutix, Inc. (NASDAQ:OCUL) regarding possible
securities law violations.

To speak privately with an attorney regarding this class action
lawsuit investigation,



Ocular Therapeutix disclosed on May 5, 2017 that it received a Form 483
from the U.S. Food and Drug Administration containing “inspectional
observations” related to the Company’s manufacturing and analytical
testing procedures.

On July 6, 2017, shortly before the end of the trading day, Seeking
Alpha published an article reporting that the Ocular Therapeutix
management may have misled investors regarding the severity of ongoing
manufacturing issues and downplayed the significance of FDA
communications regarding these issues.

Following this news, the company’s share price fell 6% on July 6, 2017,
and plummeted an additional 25% on July 7, 2017 to $7.12, causing
significant harm to investors.

If you purchased or acquired shares of Ocular Therapeutix, Inc. and
would like to speak privately with a securities attorney to learn more
about the investigation and your legal rights, visit our website
or contact the securities team directly at (800) 254-9493.

Girard Gibbs LLP is one of the nation’s leading firms representing
individual and institutional investors in securities
litigation to correct abusive corporate governance practices,
breaches of fiduciary duty, and proxy violations. The firm has recovered
over a billion dollars for its clients against some of the world’s
largest corporations, and has earned Tier-1 rankings and been named in
the U.S.
Lawyers – Best Law Firms list for five consecutive years.

This press release may constitute Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com:


Business Wire

Last updated on: 08/07/2017

Go to Source